Mayo Clinic, Rochester, Minnesota.
JAMA Cardiol. 2017 Sep 1;2(9):1030-1035. doi: 10.1001/jamacardio.2017.2249.
This review examines the current state-of-the-art optimal medical therapy (OMT) for patients with known coronary artery disease. This therapy, which is sometimes labeled as secondary prevention, is effective in preventing recurrent events and is recommended by the American College of Cardiology Foundation/American Heart Association guidelines. Optimal medical therapy is of recognized public health benefit.
The available evidence from broad patient populations, contemporary randomized trials, and multiple recent studies with pharmacy records indicates that the delivery of OMT is far from ideal. We suggest approaches for quality improvement, including better patient education, the increased use of interventions that are known to improve compliance, and the use of performance measures focused on long-term OMT in outpatient care.
Improvement in the delivery of OMT to patients with coronary artery disease is one possible step to help the United States reduce the recently reported increase in death rate from heart disease.
本篇综述审视了目前针对已知冠状动脉疾病患者的最佳药物治疗(OMT)现状。这种有时被贴上二级预防标签的疗法在预防复发事件方面非常有效,也被美国心脏病学会基金会/美国心脏协会指南推荐。最佳药物治疗具有公认的公共卫生效益。
来自广泛患者群体、当代随机试验以及最近多项使用药房记录的研究的现有证据表明,OMT 的实施远非理想。我们提出了质量改进的方法,包括更好的患者教育、增加使用已知能提高依从性的干预措施,以及使用专注于门诊长期 OMT 的绩效措施。
改善冠状动脉疾病患者的 OMT 实施可能是帮助美国降低最近报告的心脏病死亡率上升的一个步骤。